From Pathway to Model: Validation Paradigms in Cancer, Neuro, Immune and Metabolic Research

The previous pillars of this series are field-agnostic: cis-regulatory logic, epigenome editing, RNA biology, and the CRISPR strategy matrix apply wherever the question is about gene regulation.

This pillar is where the field re-enters. A dependency claim in cancer, a synaptic phenotype in neurons, a cytokine response in T cells, and a flux measurement in hepatocytes all require CRISPR tools — but they do not accept the same evidence. Each field has settled on a different set of decisive readouts, and each has a characteristic artefact that reviewers in that field will look for first.

The purpose of this article is to make those differences explicit, so that a study designed in one paradigm is not judged by the standards of another.

Read the fourth column first. It tells you what your paper will be challenged on before anyone evaluates the biology.

Cancer models are the most abundant and the most misused. Three properties determine whether a claim transfers:

• • Lineage match. A dependency defined in a colorectal line may not exist in a pancreatic one, even for the same pathway. Report the lineage and, where possible, test a second line from the same lineage.
• • Genetic background. Two lines with the same driver mutation can differ in co-occurring alterations that determine dependency. Isogenic panels isolate the driver; they do not model the tumour.
• • Microenvironment. Monoculture cannot test immune-mediated killing, hypoxia, or stromal support. Claims about those require co-culture or in vivo work, and a monoculture result should be stated as such.

Practical standard. Identify the dependency in a relevant lineage, confirm it in a second model, and state explicitly which aspect of the tumour the model does not capture.

Neurons are post-mitotic, which changes both the editing strategy and the validation requirement.

Editing. HDR-based knock-in is inefficient without division; base and prime editing, or knockout in progenitors followed by differentiation, are the practical routes. Editing before differentiation also avoids the problem of clonal selection in a non-dividing population.

Model. iPSC-derived neurons require demonstrated identity and maturity. Marker expression is not sufficient; electrophysiological maturity and network activity are the usual evidence. Report differentiation protocol, batch, and age.

Readouts. A single morphological phenotype is weak. The stronger package combines electrophysiology, imaging of activity or local translation, and where relevant a biochemical measure of the pathway. For localization claims, compartment-resolved measurement is essential, as set out in our piece on RNA localization.

Characteristic artefact. Immature neurons that respond differently from mature ones — a phenotype reported at day 20 may disappear at day 60, or appear only then.

Immune cells are usually studied as primary cells, which shifts the constraints:

Editing. RNP electroporation dominates, because short exposure improves viability and reduces off-target editing. Knock-in is feasible for reporters and for variant introduction, at lower efficiency than in lines.

Activation state. T cells and macrophages behave differently depending on activation. A perturbation applied to resting cells and read out after stimulation measures a different thing from one applied during activation. State the timing and the stimuli.

Donor variability. Human primary cells vary between donors; the replicate unit is the donor, and a single-donor claim is a single-donor claim. Pooled donors reduce variance but obscure donor-specific effects.

Readouts that carry weight. Killing assays, phagocytosis, cytokine secretion, proliferation, and transcriptome-scale state profiling. A surface marker alone is a weak endpoint.

Characteristic artefact. Supraphysiological stimulation — plate-bound antibody at high dose, or artificial APC systems — that masks or creates phenotypes absent in physiological activation.

Metabolic claims depend on the model retaining the metabolic programme being studied. This is where the field loses most of its reproducibility.

Model choice. Immortalized hepatocyte lines lose much of their metabolic capacity; primary hepatocytes dedifferentiate within days; iPSC-derived hepatocytes sit somewhere in between. Adipocytes, β cells, and myotubes each have their own dedifferentiation clock.

Readouts. Substrate flux, isotope tracing, insulin secretion, lipid handling, oxygen consumption. These are quantitative and demanding: a 20% change in flux requires careful normalization, and plate-based assays often cannot resolve it.

Normalization. Per cell, per protein, or per mitochondrial mass — each answers a different question, and the choice must be stated. Normalizing per protein can mask a change in cell size that is itself the phenotype.

Characteristic artefact. A model that no longer expresses the transporter or enzyme the pathway depends on, making the perturbation appear to have no effect.

Across all four fields, the same four properties decide whether a model can support a claim:

1. Relevance — the model expresses the pathway and reproduces the phenotype the question concerns.
2. Isogenicity — comparisons differ only in the variable of interest; otherwise a background difference is available as an explanation.
3. A functional readout — a measurement of what the pathway does, not only of what it expresses.
4. Documented stability — passage, differentiation state, karyotype, and expression at the passage used.

The fourth is the one most often absent from a methods section and most often the explanation for a result that does not reproduce.

Each of the mechanism pillars contributes a specific component to a translational model:

• • Cis-regulatory work determines whether the element, not only the coding sequence, is the relevant variable.
• • Epigenome editing supplies the durable silencing or reactivation that disease models often need.
• • RNA-level work covers the post-transcriptional mechanisms that frequently mediate the phenotype in neurons and immune cells.
• • The CRISPR strategy matrix supplies the modality choice and the QC standard that every model above depends on.

The translation problem is not a lack of tools; it is the discipline of matching the tool's evidence to the field's standard.

EDITGENE builds disease-relevant models with the validation each field requires: lineage-matched cancer lines and isogenic variant panels; iPSC-derived neurons with maturity characterization; primary immune cells edited by RNP with donor-level replication; and metabolic models with retained phenotype documentation.

Tell us the pathway, the field, and the claim you need to support — we will propose the model and the validation package that field expects. Contact EDITGENE to request a project consultation or quote.

This article describes validation standards as they are commonly applied; requirements differ by journal, subfield, and specific claim, and model performance varies by protocol and passage.

No model reproduces a human tissue completely. Claims should name what the model captures and what it does not, and should report the characterization that supports relevance.

• • Ben-David U, et al. Genetic and transcriptional evolution alters cancer cell line drug response. Nature. 2018;560:325–330.
• • Drost J, Clevers H. Organoids in cancer research. Nature Reviews Cancer. 2018;18:407–418.
• • Dolmetsch R, Geschwind DH. The human brain in a dish: the promise of iPSC-derived neurons. Cell. 2011;145:831–834.
• • Shi Y, et al. Induced pluripotent stem cell technology: a decade of progress. Nature Reviews Drug Discovery. 2017;16:115–130.
• • Shifrut E, et al. Genome-wide CRISPR screens in primary human T cells reveal key regulators of immune function. Cell. 2018;175:1951–1963.
• • Samuel VT, Shulman GI. Mechanisms for insulin resistance: common threads and missing links. Cell. 2012;148:852–871.
• • Begley CG, Ioannidis JPA. Reproducibility in science. Circulation Research. 2015;116:116–126.